Comparative Pharmacology
Head-to-head clinical analysis: KETOCONAZOLE versus TERAZOL 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOCONAZOLE versus TERAZOL 7.
KETOCONAZOLE vs TERAZOL 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane integrity.
Terconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This disruption increases membrane permeability and leads to fungal cell death.
200-400 mg orally once daily for superficial fungal infections; 400 mg orally once daily for systemic mycoses. Duration varies by indication.
Intravaginal: One full applicator (approximately 5 g of cream containing 40 mg of terconazole) inserted vaginally once daily at bedtime for 7 consecutive days.
None Documented
None Documented
Clinical Note
moderateKetoconazole + Tranilast
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast."
Clinical Note
moderateKetoconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic acid."
Clinical Note
moderateKetoconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide."
Clinical Note
moderateBiphasic elimination: initial half-life 2-4 hours, terminal half-life 6-10 hours in adults. In severe hepatic impairment, half-life may be prolonged up to 12-20 hours.
Terminal elimination half-life is approximately 7-10 hours; clinically, it allows for once-daily vaginal application, but systemic accumulation is minimal with vaginal dosing.
Primarily metabolized in the liver; about 70% of the dose is excreted in feces via bile as metabolites, approximately 20-30% in urine (mostly as inactive metabolites), and less than 5% unchanged.
Primarily fecal (approximately 60%) as unchanged drug and metabolites; renal excretion accounts for about 20% (mostly metabolites).
Category C
Category C
Azole Antifungal
Azole Antifungal
Ketoconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronic acid."